Semaglutide and tirzepatide represent new treatment modalities for type 2 diabetes mellitus (T2DM) and obesity, expanding the range of glucagon-like peptide-1 (GLP-1) receptor agonists. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.